No Data
Jenkem Technology (688356.SH): The company currently does not plan to establish its own medical aesthetics sales team.
On December 24, Glory Exchange reported that Jenkem Technology (688356.SH) stated on the investor interaction platform that regarding gel products, the company is systematically making preliminary contacts with interested parties and has not yet formed substantial agreements. The company currently still does not plan to establish a medical beauty sales team. For specific subsequent updates, please refer to the company's official disclosures.
Jenkem Technology's Unit Completes Enrollment of First Subject for Polyethylene Glycol Irinotecan for Injection Trial
Jenkem Technology (688356.SH): The first subject enrolled in the phase II clinical trial of Polyethylene Glycol Iletocan used to treat triple-negative breast cancer with brain metastases.
Gelonghui November 12th, Jenkem Technology (688356.SH) announced that the independently developed injection polyethylene glycol irinotecan (pharmaceutical code: JK1201I) for the treatment of brain metastasis associated triple-negative breast cancer phase II clinical trial "JK1201I treatment of triple-negative breast cancer II clinical study with brain metastasis" has recently completed the enrollment of the first subject.
After the Recent Decline, Jenkem Technology Co., Ltd. (SHSE:688356) CEO Xuan Zhao's Holdings Have Lost 11% of Their Value
2024 THIRD QUARTER REPORT (CORRECTED)
Corrections to the 2024 Third Quarter Report
Should Weakness in Jenkem Technology Co., Ltd.'s (SHSE:688356) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
No Data
